The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker

Journal of Surgical Oncology

Volumn 114, Issue 7, 2016, Pages 895-899

  Køstner, Anne Helene ^a   Kersten, Christian ^a   Löwenmark, Thyra ^b   Ydsten, Karin A ^c   Peltonen, Reetta ^d,e   Isoniemi, Helena ^d   Haglund, Caj ^d,e   Gunnarsson, Ulf ^b   Isaksson, Bengt ^c  

^a Southern Hospital Trust   (Norway)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

C reactive protein; colorectal cancer; Glasgow prognostic score; liver metastases; systemic inflammatory response

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; FEMALE; GLASGOW PROGNOSTIC SCORE; HISTOPATHOLOGY; HUMAN; HYPOALBUMINEMIA; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; BLOOD; COLORECTAL TUMOR; FOLLOW UP; LIVER NEOPLASMS; LIVER RESECTION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; INFLAMMATION; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84992463454     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24415     Document Type: Article

References (26)

1. Guthrie GJ, Roxburg CS, Farhan-Alaine OM, et al.: Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer 2013; 109:24–28.
2. Hamilton TD, Leugner D, Kopciuk K, et al.: Identification of prognostic inflammatory factors in colorectal liver metastases. BMC Cancer 2014; 14:542.
3. Ayez N, Lalmahomed ZS, van der Pool AE, et al.: Is the clinical risk score for patients with colorectal liver metastases still useable in the era of effective neoadjuvant chemotherapy? Ann Surg Oncol 2011; 18:2757–2763.
4. Pulitano C, Bodingbauer M, Aldrighetti L, et al.: Liver resection for colorectal metastases in presence of extrahepatic disease: Results from an international multi-institutional analysis. Ann Surg Oncol 2011; 18:1380–1388.
5. Vayrynen JP, Tumomisto A, Klintrup K, et al.: Detailed analysis of inflammatory cell infiltration in colorectal cancer. Br J Cancer 2013; 109:1839–1847.
6. Roxburgh CS, McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010; 6:149–163.
7. Park JH, Watt DG, Roxburgh CS, et al.: Colorectal cancer, systemic inflammation, and outcome: Staging the tumor and staging the host. Ann Surg 2016; 263:326–336.
8. Shrotriya S, Walsh D, Bennani-Baiti N, et al.: C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic review. PLoS ONE 2015; 10:e0143080.
9. Dutta S, Crumley AB, Fullarton GM, et al.: Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg 2012; 204:294–299.
10. Toiyama Y, Inoue Y, Saigusa S, et al.: C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery. Anticancer Res 2013; 33:5065–5074.
11. Goyal A, Terry MB, Jin Z, et al.: C-reactive protein and colorectal cancer mortality in U.S. adults. Cancer Epidemiol Biomarkers Prev 2014; 23:1609–1618.
12. Kersten C, Louhimo J, Algars A, et al.: Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol 2013; 52:1691–1698.
13. Thomsen M., Kersten C, Sorbye H, et al.: C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study. in ASCO Annual Meeting Proceedings. 2015.
14. McMillan DC: The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer. Cancer Treat Rev 2013; 39:534–540.
15. Wong VK, Malik HZ, Hamady ZZ, et al.: C-reactive protein as a predictor of prognosis following curative resection for colorectal liver metastases. Br J Cancer 2007; 96:222–225.
16. Maeda K, Shibutani M, Otani H, et al.: Inflammation-based factors and prognosis in patients with colorectal cancer. World J Gastrointest Oncol 2015; 7:111–117.
17. Mori K, Toiyama Y, Saigusa S, et al.: Systemic analysis of predictive biomarkers for recurrence in colorectal cancer patients treated with curative surgery. Dig Dis Sci 2015; 60:2477–2487.
18. Guthrie GJ, Roxburgh CS, Richards CH, et al.: Circulating IL-6 concentrations link tumour necrosis and systemic and local inflammatory responses in patients undergoing resection for colorectal cancer. Br J Cancer 2013; 109:131–137.
19. Nazha B, Moussaly E, Zaarour M, et al.: Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? World J Gastrointest Surg 2015; 7:370–377.
20. Yao X, Huang J, Zhong H, et al.: Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther 2014; 141:125–139.
21. Wu J, Cai Q, Li H, et al.: Circulating C-reactive protein and colorectal cancer risk: A report from the Shanghai Men's Health Study. Carcinogenesis 2013; 34:2799–2803.
22. Nakagawa K, Tanaka K, Nojiri K, et al.: The modified Glasgow prognostic score as a predictor of survival after hepatectomy for colorectal liver metastases. Ann Surg Oncol 2014; 21:1711–1718.
23. Rayburn E, Ezell SJ, Zhang R, et al.: Anti-inflammatory agents for cancer therapy. Mol Cell Pharmacol 2009; 1:29–43.
24. Bains SJ, Mahic M, Myklebust TA, et al.: Aspirin as secondary prevention in patients with colorectal cancer: An unselected population-based study. JCO 2016; 32:2501–2508.
25. Roxburgh CSD, McMillan DC: Cancer and systemic inflammation: Treat the tumour and treat the host. Br J Cancer 2014; 110:1409–1412.
26. Guo Y, Xu F, Lu T, et al.: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 2012; 38:904–910.